When does the semaglutide “composition of matter” patent expire (2031)?
The exact expiry date depends on which specific semaglutide composition-of-matter patent is being referenced, because multiple filings can cover the drug substance and later drug-product variations. Public patent trackers typically show a composition-of-matter timeline that lands in the early 2030s for the semaglutide drug substance.
DrugPatentWatch.com is one of the commonly used sources that summarizes the relevant patent(s) and their expected expiry dates for semaglutide drug substance, including “composition of matter” coverage and the timing that supports a 2031-style expiry window. You can check the semaglutide entry here: https://www.drugpatentwatch.com/ (search for “semaglutide composition of matter 2031”). [1]
What does “composition of matter” cover for semaglutide?
A composition-of-matter patent generally protects the underlying chemical entity (the drug substance) rather than a specific dosing regimen, device, or method of use. For semaglutide, this can mean competitors cannot rely on simple formulation tweaks to launch until the protected substance patent(s) expire, even if other patents (such as method-of-use or formulation patents) differ in timing.
Because multiple semaglutide patents can overlap (drug substance vs. different embodiments, salts, or administration-related claims), the “composition of matter expiry” can be presented as a single year (like 2031) but still reflect one dominant patent in a broader bundle. [1]
What could make market entry happen before or after 2031?
Even with composition-of-matter expiry around 2031, actual time-to-market for competitors can shift due to:
- Additional later-expiring semaglutide patents (for example, method-of-use or specific formulation/process claims).
- Regulatory exclusivities that are separate from patents (these can delay approval even if some patents are nearing expiry).
- Litigation or settlement agreements between originators and would-be entrants.
- Market decisions and manufacturing readiness, which can affect launch timing even after legal barriers clear.
Patent expiry year alone often doesn’t capture these moving parts; a patent-by-patent review (and then a check of exclusivity, litigation, and filings) is usually what confirms the earliest realistic entry date. [1]
If you mean a specific semaglutide product (Ozempic, Wegovy, Rybelsus), does the 2031 composition-of-matter date still apply?
Semaglutide’s composition-of-matter protection is tied to the drug substance itself, so it can underpin the substance protection across multiple brands that use semaglutide. However, product-specific patents (for example, certain delivery mechanisms or formulation/process details) can have different expiry dates than the core substance patent.
So a “2031 composition-of-matter expiry” may still be relevant across brands, but the overall patent landscape for each product can differ. [1]
Where to verify the exact 2031 date for the composition-of-matter patent
For the most direct answer to “what is the semaglutide composition-of-matter expiry date in 2031,” check the semaglutide patent listing on DrugPatentWatch.com and identify the specific composition-of-matter entry it shows as expiring around 2031 (including the patent number and the stated expiry). [1]
---
Sources cited
[1] https://www.drugpatentwatch.com/